Mental health AI
Therabot
Therabot is assessed here as a supervised research deployment. Trial participation and researcher oversight do not establish the controls of a current commercial product. Its former 45 is retained as history, outside current consumer-score comparisons.
Supervised research does not establish a current consumer-product score. Historical scores are retained in the report.
Summary judgment · Unscored in current comparisons
Supervised research does not establish a current consumer-product score. Historical axis: 45/100.
Research-stage, unclear in deployment
Therabot is assessed here as a supervised research deployment. Trial participation and researcher oversight do not establish the controls of a current commercial product. Its former 45 is retained as history, outside current consumer-score comparisons.
Patient agency
How this tool changes agency
Symptom improvement and therapeutic alliance do not themselves demonstrate patients becoming better able to interrogate advice, evaluate evidence or redirect therapeutic goals.
Public commercial availability and governance are not established by the bounded institutional-source pass
Patient agency assessment
Who sets and changes the goal?
Participants could initiate conversations inside a researcher-governed intervention. Enrollment restrictions are a research scope boundary, not evidence of coercion or diminished agency within participation.
What can the patient understand, question, or do?
Symptom improvement and therapeutic alliance do not themselves demonstrate patients becoming better able to interrogate advice, evaluate evidence or redirect therapeutic goals.
Can the patient evaluate the conditions of use?
Supervision is documented for the trial. Future commercial privacy, withdrawal, correction and oversight cannot be inferred from research safeguards.
Text findings
Conditions of use
Published controls and their limits
Supervision is documented for the trial. Future commercial privacy, withdrawal, correction and oversight cannot be inferred from research safeguards.
What remains unknown?
Not tested or not established
Public commercial availability and governance are not established by the bounded institutional-source pass
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
- https://home.dartmouth.edu/news/2025/03/first-therapy-chatbot-trial-yields-mental-health-benefits
- https://home.dartmouth.edu/news/2026/04/brian-pogue-and-nick-jacobson-receive-innovation-awards
Source-specific findings and retrieval limitations are recorded in the full report.
Review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Public commercial availability and governance are not established by the bounded institutional-source pass No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
Research deployment · Moderate for historical trial deployment, low for present commercialization (AI-assisted draft)